0.36
-0.028(-7.29%)
Currency In USD
| Previous Close | 0.38 |
| Open | 0.37 |
| Day High | 0.38 |
| Day Low | 0.33 |
| 52-Week High | 99 |
| 52-Week Low | 0.31 |
| Volume | 565,197 |
| Average Volume | 3.91M |
| Market Cap | 3.71M |
| PE | -0.01 |
| EPS | -60.57 |
| Moving Average 50 Days | 1.74 |
| Moving Average 200 Days | 25.96 |
| Change | -0.03 |
If you invested $1000 in GlucoTrack, Inc. (GCTK) 10 years ago, it would be worth $0.05 as of March 12, 2025 at a share price of $0.356. Whereas If you bought $1000 worth of GlucoTrack, Inc. (GCTK) shares 5 years ago, it would be worth $0.55 as of March 12, 2025 at a share price of $0.356.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member
GlobeNewswire Inc.
Feb 26, 2025 1:01 PM GMT
Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technologyRUTHERFORD, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical de
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
GlobeNewswire Inc.
Feb 04, 2025 5:24 PM GMT
Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a “b
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
GlobeNewswire Inc.
Feb 04, 2025 1:01 PM GMT
The study met its primary endpoint with no procedure or device related serious adverse events reportedRUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company